作者: Sofy Permana , Reyudzky Putri Fityanti , Eviana Norahmawati , Agustin Iskandar , Erika Desy Anggraini Mulyadi
DOI: 10.1155/2020/9418520
关键词: Colitis 、 Vimentin 、 Risk factor 、 Gastroenterology 、 Ulcerative colitis 、 DNA damage 、 Colorectal cancer 、 Internal medicine 、 Cetuximab 、 Eisenia fetida 、 Medicine
摘要: Ulcerative colitis is a major risk factor that increases the occurrence of colorectal cancer. In cancer due to colitis, intestinal inflammation plays an important role which causes DNA damage. The aim this study investigate anticancer effect coelomic fluid Eisenia fetida (CFEF) and cetuximab combinations. Colitis associated colon was induced in BALB/c mice by DSS/AOM. were randomly divided into six groups: group 1 received vehicle (control), groups 2–6 DSS/AOM, 3–5 cetuximab + CFEF (30, 60, or 120 mg/kgBW), 6 CFEF only. After 12th week treatments, tissues removed for histological examination immune-fluorescence. Intestinal Epithelial Cells (CECs) analyzed flow cytometer. Administration significantly decreased severity DSS/AOM-induced CAC dose-dependent manner. combinations CFEF-cetuximab revealed change. reduced scores ( ). inhibited K-Ras vimentin expressions, whereas percentage RUNX3 increased CECs. increasing could prevent EMT, so it can decrease suppressed cell invasion migration CFEF. Our results suggest has therapeutic potential CAC.